Middle East and Asia Pacific BiotechnologyExpanding Rapidly
Government Support Driving Growth in the Region
Government support for research and development has been a major driver of growth for the biotechnology industry in the Middle East and Asia Pacific regions. Countries such as China, India, South Korea, Singapore, and Israel have all established robust funding programs and incentives to encourage local biotech startup formation and attract multinational companies to set up regional hubs. This support has helped transform the biotech landscape in recent decades.
China's Commitment to Biotech Leadership
China has potentially the most ambitious Middle East and Asia Pacific Biotechnology goals and support programs in the region. The Chinese government has identified biotechnology as one of seven strategic emerging industries and aims to build China into a global biotech innovation center. Massive funding is allocated for R&D through national programs such as the National Key R&D Plan. Tax incentives are provided for qualified biotech companies, and landmark projects like the Zhangjiang National Innovation Demonstration Zone near Shanghai have been created as biotech industry hubs.
As a result, China has seen enormous growth in its biotech industry in recent years. The country is now among the top five global destinations for biotech investment and clinical trials. Major domestic companies such as BeiGene and Innovent Biologics are emerging as global leaders in areas like oncology. Meanwhile, every large Western biotech company has established a major presence in China to access its vast population for clinical trials and future commercial opportunities.
Middle East and Asia Pacific Biotechnology as Regional Biomanufacturing Powerhouse
Like China, India has employed government support to rapidly scale up its domestic biotechnology industry. The Indian government's Department of Biotechnology oversees funding programs that have helped produce a large number of biotech startups concentrated in hubs around major cities. Tax breaks are provided for R&D expenditures. In addition, India's strong capabilities in generics manufacturing have positioned it to become a leading exporter of biosimilars.
As biomanufacturing and clinical capabilities have expanded, major contract research and manufacturing organizations (CROs and CMOs) from the US and Europe have established operations in India. The country is now one of the top destinations globally for outsourced biologics production. Indian firms such as Biocon and Serum Institute of India are also emerging as independent forces in biologics thanks to their vaccine and biosimilar portfolios. Going forward, investments in cell and gene therapy infrastructure could further strengthen India's position in biomanufacturing.
Middle East and Asia Pacific Biotechnology to Transform Its Economy
The South Korean government has taken a strong approach to nurturing strategic industries as part of its economic development model. Biotechnology has been identified as one such industry since the late 1990s. Major funding programs support biotech initiatives, and the government regulates to ensure technology adoption in areas like biosimilars.
Get more insights on Middle East And Asia Pacific Biotechnology
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian